CSPC Pharmaceutical 9M profit jumps on Astrazeneca licence fee boost
Overview
China pharmaceutical group's nine-month revenue rose 27% yr/yr, driven by finished drugs and licence fees
Net profit attributable to shareholders more than doubled, up 101.5% yr/yr
Bulk products and functional food revenues declined due to lower prices and competition
Outlook
CSPC Pharmaceutical is eligible for up to $3.5 bln development and $13.8 bln sales milestones from AstraZeneca
Result Drivers
ASTRAZENECA LICENCE INCOME – RMB5.74 bln of the upfront payment was recognised as licence fee income, contributing significant Group revenue
FINISHED DRUGS GROWTH - Finished drugs revenue rose 40.1%, driven by higher sales in nervous system and digestion/metabolism therapeutic areas and increased licence fees
VITAMIN C PRICING – Vitamin C revenue fell 18.9% to RMB1,451 mln, which the Co said was primarily due to lower selling prices
ANTIBIOTICS COMPETITION – Antibiotics revenue fell 27.3% to RMB885 mln, which the Co said was mainly due to intensified competition and volume-based procurement
Company press release: Full Story
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
9M Revenue | RMB 25.26 bln | ||
9M Net Income Attributable | RMB 7.08 bln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for CSPC PHARMACEUTICAL GROUP LIMITED is HK$12.00, about 52.1% above its November 17 closing price of HK$7.89
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago
Reuters Recommended Reads
Nov 16 - AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Nov 16 - ALX Oncology Q3 net loss per share narrows
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)